Bioiberica closed 2008 by participating in the three most important international conferences on diseases of the musculoskeletal system: those organized by EULAR, OARSI and ACR.
Bioiberica presented new clinical-efficacy and safety data on chondroitin, as well as a new line of scientific research on the product as a modulator of chronic inflammation.